본문 바로가기


기관정보 기관정보상세


학회명 국문 대한류마티스학회 기관구분 학회
영문 Korean College of Rheumatology 제재이력 변경이력
전화번호   팩스번호  
홈페이지 www.rheum.or.kr 이메일  
주소 [04378] 서울특별시 용산구 한강대로 95, A동 1917호 (한강로2가, 래미안용산)
대표자 성명 최정윤
소속 대구가톨릭대학교 직위 교수
임기 2016-05-22 ~ 2018-05-21
실무자 성명 김현정 연락처(핸드폰)
연구분야 의학정보
행정인력수 2명 전임연구인력수 0명
설립구분 기타 설립일자 1979-10-25
											대한 류마티스학회는 1979년 10월 25일 창립된 학회로서 대한의학회 산하 학술단체로 등록되어 있다. 주된 사업은 연 2회의 류마티스학 연구 발표 및 학술강연회 개최, 연 3회의 류마티스학자 혹은 개원의를 위한 연수강좌, 류마티스학 교과서 발행, 류마티스학의 학습 및 보급, 학회지 및 기타 간행물 발간과 이사회 및 총회 결의에 따른 제반 사업을 수행하고 있다. 설립 초기에는 대한 정형외과학회의 분과학회로 출발하였고, 정형외과 전공자들이 회원의 다수를 점하였으나. 1990년을 전후로 류마티스내과를 위시하여 피부과 재활의학과, 소아청소년과를 전공한 연구자의 비율이 점차 증가하고 있다. 아울러 1994년 대한류마티스학회지의 발간에 즈음하여 학회 회원의 국제학회의 참여가 괄목할 만하게 증가하였고, SCI 논문의 출판도 연 수십 편을 상회할 정도로 현저하게 증가하고 있는 중이다. 학회 활동은 춘계, 추계학술대회 개최를 하고 있으며, 1999년부터 한일 공동으로 격년제로 개최 해 왔던 한일류마티스학회를 2005년부터는 중국도 포함하여 한.중.일 류마티스학회로 발전해 개최 해 왔고 2013년부터는 대만과 홍콩까지 합류하여 동아시아 류마티스학회(East Asian Group of Rheumatology)로 발전 해 왔다. 국제 학회는 1990년 아세아 태평양 류마티스학회(APLAR) 국제 심포지움을 개최한 바 있고, 2004년 9월 11일~15일까지 제11차 아시아태평양 국제류마티스학회(the Asia Pacific League Against Rheumatism, 일명 APLAR)를 제주에서 개최할 정도로 학술적으로 많은 발전을 하였으며 활발한 국제 교류와 아울러 국제적 위상도 크게 향상 되었다. 1994년부터 발행한 대한류마티스학회 학회지는 2011년 Journal of Rheumatic Diseases로 명칭을 변경하였으며 2012년부터는 Journal of Rheumatic Diseases 학술지를 연 6회 발행하였으며, 2018년부터 다시 연 4회 발행하고 있다.

연구윤리제정일 2008-09-30 원문서비스url http://www.jrd.or.kr/
										Research and Publication Ethics

For the policies on research and publication ethics not stated in the Instructions, Guidelines on Good Publication (http://publicationethics.org/) or Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/) can be applied.

1) Conflict-of-Interest statement
Conflict of interest exists when an author or the author's institution, reviewer, or editor has financial or personal relationships that inappropriately influence or bias his or her actions. Such relationships are also known as dual commitments, competing interests, or competing loyalties. These relationships vary from being negligible to having great a potential for influencing judgment. Not all relationships represent true conflict of interest. On the other hand, the potential for conflict of interest can exist regardless of whether an individual believes that the relationship affects his or her scientific judgment. Financial relationships such as employment, consultancies, stock ownership, honoraria, and paid expert testimony are the most easily identifiable conflicts of interest and the most likely to undermine the credibility of the journal, the authors, or of the science itself. Conflicts can occur for other reasons as well, such as personal relationships, academic competition, and intellectual passion (http://www.icmje.org/conflicts-of-interest/). If there are any conflicts of interest, authors should disclose them in the manuscript. The conflicts of interest may occur during the research process as well; however, it is important to provide disclosure. If there is a disclosure, editors, reviewers, and reader can approach the manuscript after understanding the situation and background for the completed research.

2) Statement of human and animal right
Clinical research should be done in accordance with the Ethical Principles for Medical Research Involving Human Subjects, as outlined in the Helsinki Declaration of 1975 (revised 2008) (available from: http://www.wma.net/en/30publications/10policies/b3/). Clinical studies that do not meet the Helsinki Declaration will not be considered for publication. For publication, the human subjects' identifiable information, such as the patients' names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. For animal subjects, the research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.

3) Statement of informed consent and Institutional Review Board approval
Copies of written informed consents should be kept for studies on human subjects. For the clinical studies with human subjects, there should be a certificate, an agreement, or the approval by the Institutional Review Board (IRB) of the author's affiliated institution. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct.

4) Registration of the clinical trial research
Any research that deals with a clinical trial should be registered with the primary national clinical trial registry site such as the Korea Clinical Research Information Service (CRiS, http://cris. nih.go.kr), other primary national registry sites accredited by the World Health Organization (http://www.who.int/ictrp/network/primary/en/) or ClinicalTrials.gov (http://clinicaltrials.gov/), a service of the United States National Institutes of Health.

5) Authorship
Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreeing to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet these 4 conditions. If the number of authors is greater than 6, there should be a list of each author's role in the submitted paper. If any persons who do not meet the above four criteria, they may be placed as contributors in the Acknowledgments section. Description of co-first authors or co-corresponding authors is also accepted if the corresponding author believes that such roles existed in contributing to the manuscript.

6) Originality and duplicate publication
All submitted manuscripts should be original and should not be in consideration by other scientific journals for publication. Any part of the accepted manuscript should not be duplicated in any other scientific journal without the permission of the Editorial Board, although the figures and tables can be used freely if the original source is verified according to Creative Commons license. It is mandatory for all authors to resolve any copyright issues when citing a figure or table from other journal that is not open access.

7) Secondary publication
It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by International Committee of Medical Journal Editors (ICMJE), available from http://www.icmje.org/. These are: • The authors have received approval from the editors of both journals (the editor concerned with the secondary publication must have access to the primary version).
• The priority for the primary publication is respected by a publication interval negotiated by editors of both journals and the authors.
• The paper for secondary publication is intended for a different group of readers; an abbreviated version could be sufficient.
• The secondary version faithfully reflects the data and interpretations of the primary version.
• The secondary version informs readers, peers, and documenting agencies that the paper has been published in whole or in part elsewhere—for example, with a note that might read, "This article is based on a study first reported in the [journal title, with full reference]"—and the secondary version cites the primary reference.
• The title of the secondary publication should indicate that it is a secondary publication (complete or abridged republication or translation) of a primary publication. Of note, the United States National Library of Medicine (NLM) does not consider translations to be "republications" and does not cite or index them when the original article was published in a journal that is indexed in MEDLINE.

8) Process to manage the research and publication misconduct
When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author's idea or data, complaints against editors, and other issues, the resolving process will be followed by flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The discussion and decision on the suspected cases are done by Editorial Board of JRD.
연구윤리파일 Research and Publication Ethics.hwp   다운로드